BR112021024300A2 - Formas de sais cristalinas de um inibidor de quinase - Google Patents

Formas de sais cristalinas de um inibidor de quinase

Info

Publication number
BR112021024300A2
BR112021024300A2 BR112021024300A BR112021024300A BR112021024300A2 BR 112021024300 A2 BR112021024300 A2 BR 112021024300A2 BR 112021024300 A BR112021024300 A BR 112021024300A BR 112021024300 A BR112021024300 A BR 112021024300A BR 112021024300 A2 BR112021024300 A2 BR 112021024300A2
Authority
BR
Brazil
Prior art keywords
kinase inhibitor
salt forms
crystalline salt
crystalline
relates
Prior art date
Application number
BR112021024300A
Other languages
English (en)
Inventor
S Johnson Courtney
Frenel Demorin
Khalid Shah
Janelle Bevill Melanie
Peter Wong
Sagar Shakya
D Parent Stephan
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of BR112021024300A2 publication Critical patent/BR112021024300A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

formas de sais cristalinas de um inibidor de quinase. a presente invenção se refere a formas cristalinas de sais do composto 1. a invenção também se refere a composições farmacêuticas que compreendem os sais cristalinos sólidos do composto 1. a invenção se refere ainda a métodos de tratamento de uma doença, distúrbio ou síndrome mediada pelo menos em parte pela modulação da atividade in vivo de uma proteína quinase.
BR112021024300A 2019-06-03 2019-12-12 Formas de sais cristalinas de um inibidor de quinase BR112021024300A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962856404P 2019-06-03 2019-06-03
PCT/US2019/065980 WO2020247019A1 (en) 2019-06-03 2019-12-12 Crystalline salt forms of a kinase inhibitor

Publications (1)

Publication Number Publication Date
BR112021024300A2 true BR112021024300A2 (pt) 2022-01-11

Family

ID=69160360

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021024300A BR112021024300A2 (pt) 2019-06-03 2019-12-12 Formas de sais cristalinas de um inibidor de quinase

Country Status (19)

Country Link
US (1) US20230052703A1 (pt)
EP (1) EP3976587A1 (pt)
JP (1) JP2022535072A (pt)
KR (1) KR20220016117A (pt)
CN (1) CN113939503B (pt)
AU (1) AU2019449809A1 (pt)
BR (1) BR112021024300A2 (pt)
CA (1) CA3139148A1 (pt)
CL (1) CL2021003205A1 (pt)
CO (1) CO2021017343A2 (pt)
CR (1) CR20210616A (pt)
DO (1) DOP2021000236A (pt)
GE (1) GEP20247655B (pt)
IL (1) IL288484A (pt)
MA (1) MA56001A (pt)
MX (1) MX2021014773A (pt)
PE (1) PE20220962A1 (pt)
SG (1) SG11202111978VA (pt)
WO (1) WO2020247019A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019148044A1 (en) * 2018-01-26 2019-08-01 Exelixis, Inc. Compounds for the treatment of kinase-dependent disorders
CN113329790A (zh) * 2018-12-13 2021-08-31 埃克塞里艾克西斯公司 激酶抑制剂的结晶形式和盐形式
TW202334090A (zh) * 2021-11-03 2023-09-01 美商艾克塞里克斯公司 用於治療激酶依賴性病症之化合物
WO2023122739A1 (en) 2021-12-22 2023-06-29 Exelixis, Inc. Crystalline forms and salt forms of a kinase inhibitor

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE517091T1 (de) * 2003-09-26 2011-08-15 Exelixis Inc C-met-modulatoren und verwendungsverfahren
AU2006236508B2 (en) 2005-04-15 2012-02-02 Precision Biologics, Inc. Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
CN107892719B (zh) 2012-10-04 2022-01-14 达纳－法伯癌症研究所公司 人单克隆抗-pd-l1抗体和使用方法
JP6742903B2 (ja) 2013-05-02 2020-08-19 アナプティスバイオ インコーポレイティッド プログラム死−１（ｐｄ−１）に対する抗体
US20180009758A1 (en) * 2015-06-29 2018-01-11 Ontogenesis, Llc Multi-Tyrosine Kinase Inhibitors Derivatives and Methods of Use
MX2019012505A (es) * 2017-05-26 2019-12-19 Exelixis Inc Formas solidas cristalinas de sales de ciclopropano-1,1-dicarboxam ida de n-{4-[(6,7-dimetoxiquinolin-4-il)oxi]fenil}-n'-(4-fluorofen il), procesos para realizarlas y metodos de uso.
WO2019148044A1 (en) 2018-01-26 2019-08-01 Exelixis, Inc. Compounds for the treatment of kinase-dependent disorders
CN109761899B (zh) * 2019-02-14 2022-11-15 广州六顺生物科技股份有限公司 喹啉衍生物、其药学上可接受的盐或其溶剂合物、其应用、药物及药物组合物

Also Published As

Publication number Publication date
CO2021017343A2 (es) 2022-01-17
AU2019449809A1 (en) 2021-12-16
CL2021003205A1 (es) 2022-09-30
EP3976587A1 (en) 2022-04-06
CA3139148A1 (en) 2020-12-10
WO2020247019A1 (en) 2020-12-10
CN113939503A (zh) 2022-01-14
DOP2021000236A (es) 2022-04-18
MX2021014773A (es) 2022-01-18
KR20220016117A (ko) 2022-02-08
GEP20247655B (en) 2024-08-26
US20230052703A1 (en) 2023-02-16
SG11202111978VA (en) 2021-11-29
CN113939503B (zh) 2024-05-07
MA56001A (fr) 2022-04-06
CR20210616A (es) 2022-03-22
IL288484A (en) 2022-01-01
PE20220962A1 (es) 2022-06-10
JP2022535072A (ja) 2022-08-04

Similar Documents

Publication Publication Date Title
BR112021024300A2 (pt) Formas de sais cristalinas de um inibidor de quinase
PH12021551356A1 (en) Crystalline forms and salt forms of a kinase inhibitor
BR112018002499A2 (pt) método de preparação de um composto da fórmula (a) ou um seu sal, solvato ou conjugado de aminoácido farmaceuticamente aceitável, composto produzido pelo método e composição farmacêutica
EA201792214A1 (ru) Соединения замещенного хиназолина
BR112019002275A2 (pt) inibidores aminopirimidina de ssaos
BR112015022785A2 (pt) composto; composição farmacêutica; kit ou artigo farmacêutico embalado; método de inibição de uma arginina metil transferase (rmt); método de modulação da expressão genética; método de modulação da transcrição; e método de tratamento de um distúrbio mediado por rmt
BR112013021236A2 (pt) composto, composição,e, método de tratamento de um distúrbio, uma condição ou uma doença
BR112018001534A2 (pt) inibidor de isocitrato desidrogenase idh1 r132h mutante
BR112018073524A2 (pt) composto, composição farmacêutica, combinação, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, método de tratamento de uma doença ou condição.
BR112018006545A2 (pt) ?composto, composição farmacêutica, combinação, uso de um composto, e, método para tratamento de uma doença ou condição?
BR112023001792A2 (pt) Combinações para o tratamento de câncer
BR112021023927A2 (pt) Composto, e, composição farmacêutica
BR112021022651A2 (pt) Subunidade s1 modificada da proteína spike de coronavírus
BR112017026272A2 (pt) ?composto, composição farmacêutica, método para o tratamento de uma desordem relacionada a receptor m1 muscarínico e uso do composto?
EA201990095A1 (ru) КОНДЕНСИРОВАННЫЕ ТИОФЕНОВЫЕ ПРОИЗВОДНЫЕ, ПРИЕМЛЕМЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ NAPI-IIb
BR112021023765A2 (pt) Composto de fórmula (1), um isômero óptico, uma forma cristalina ou um sal farmaceuticamente aceitável do mesmo, inibidor de aurora quinase, composição farmacêutica de combinação e aplicação do composto
BR112016020556A8 (pt) compostos, composição farmacêutica, método de modulação da atividade do receptor de grelina, método para o tratamento de uma doença e usos de um composto
CR20230223A (es) Composiciones farmacéuticas de un inhibidor de cinasa
BR112017020053A2 (pt) novo composto heterocíclico, método para a preparação do mesmo e composição farmacêutica compreendendo o mesmo
BR112022024700A2 (pt) Inibidores de atr e usos dos mesmos
BR112021025079A2 (pt) Composto, uso de um composto, método para o tratamento ou profilaxia de doenças e condições afetadas pela modulação de tmem16a e composição farmacêutica
BR112021024955A2 (pt) Inibidores de piridila ou pirimidila da quinase mtor
BR112019002151A2 (pt) usos de compostos de fórmula (i) e usos de uma composição
CY1124087T1 (el) Παραγωγα πυριδοκιναζολινης χρησιμα ως αναστολεις πρωτεϊνικων κινασων
EA202191653A1 (ru) Кристаллические формы и солевые формы ингибитора киназы

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]